💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Abiraterone Acetate

CHEMBL271227 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
391.5 g/mol
LogP
5.2
Phase
4

Androgen synthesis continues in the adrenal glands and within tumour tissue even after testicular suppression, and abiraterone acetate addresses that residual production by inhibiting CYP17, an enzyme required at an early step of the pathway. Lowering androgen concentrations throughout the body makes the drug effective in advanced prostate cancer that progresses despite standard hormone therapy. Blocking CYP17 also diverts steroid synthesis toward mineralocorticoids, which is why a corticosteroid such as prednisone accompanies treatment to offset the resulting hormonal effects. Blood pressure and hepatic function are monitored during therapy, both reflecting predictable consequences of altered steroid synthesis. The compound is C26H33NO2 with a molecular weight near 391.5 g/mol.

An oral medication that lowers testosterone and other androgens throughout the body by blocking an enzyme called CYP17 involved in their production. It is used to treat advanced prostate cancer that continues to grow despite standard hormone therapy, and must always be taken with a corticosteroid such as prednisone to prevent certain hormonal side effects. Patients need regular blood pressure and liver function monitoring during treatment.

Молекулярная масса

391,5000 g/mol

LogP

5,20

TPSA

39,20 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Endocrinology Oncology Prostate Cancer

Механизм действия

Abiraterone acetate is a prodrug hydrolysed to abiraterone, a selective and irreversible inhibitor of CYP17A1 (17-alpha-hydroxylase / C17,20-lyase). Blocking this single enzyme halts androgen synthesis in the testes, the adrenal glands and within prostate tumour tissue itself. Because CYP17A1 blockade diverts precursors into the mineralocorticoid pathway, it is given together with a corticosteroid to suppress the resulting ACTH drive.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Abiraterone acetate is a prodrug hydrolysed to abiraterone, a selective and irreversible inhibitor of CYP17A1 (17-alpha-hydroxylase / C17,20-lyase). Blocking this single enzyme halts androgen synthesis in the testes, the adrenal …

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]2(C)C(c4cccnc4)=CC[C@@H]32)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C26H33NO2

                    

                    
                    

                        
HBD / HBA

                        
- / 3

                    

                    
                    

                        
Вращаемые Связи

                        
3

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
29

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
An oral medication that lowers testosterone and other androgens throughout the body by blocking an enzyme called CYP17 involved in their production. It is used to treat advanced prostate cancer that continues to grow despite standard hormone therapy, and must always be taken with a corticosteroid such as prednisone to prevent certain hormonal side effects. Patients need regular blood pressure and liver function monitoring during treatment.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Abiraterone acetate is a prodrug hydrolysed to abiraterone, a selective and irreversible inhibitor of CYP17A1 (17-alpha-hydroxylase / C17,20-lyase). Blocking this single enzyme halts androgen synthesis in the testes, the adrenal glands and within prostate tumour tissue itself. Because CYP17A1 blockade diverts precursors into the mineralocorticoid pathway, it is given together with a corticosteroid to suppress the resulting ACTH drive.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Abiraterone Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL271227.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9821849.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.